
Jacob B. Marks
Examiner (ID: 10892, Phone: (571)270-7873 , Office: P/1729 )
| Most Active Art Unit | 1729 |
| Art Unit(s) | 1729, 1795 |
| Total Applications | 1014 |
| Issued Applications | 810 |
| Pending Applications | 1 |
| Abandoned Applications | 205 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18223482
[patent_doc_number] => 20230062476
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => GENETICALLY MODIFIED MEGAKARYOCYTE, MODIFIED PLATELET, AND METHODS RESPECTIVELY FOR PRODUCING SAID GENETICALLY MODIFIED MEGAKARYOCYTE AND SAID MODIFIED PLATELET
[patent_app_type] => utility
[patent_app_number] => 17/797551
[patent_app_country] => US
[patent_app_date] => 2021-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9270
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17797551
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/797551 | GENETICALLY MODIFIED MEGAKARYOCYTE, MODIFIED PLATELET, AND METHODS RESPECTIVELY FOR PRODUCING SAID GENETICALLY MODIFIED MEGAKARYOCYTE AND SAID MODIFIED PLATELET | Feb 28, 2021 | Pending |
Array
(
[id] => 18265433
[patent_doc_number] => 20230086675
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => TUMOR-INFILTRATING LYMPHOCYTES WITH ENHANCED TUMOR REACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/905131
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5825
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905131
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/905131 | TUMOR-INFILTRATING LYMPHOCYTES WITH ENHANCED TUMOR REACTIVITY | Feb 25, 2021 | Pending |
Array
(
[id] => 17067539
[patent_doc_number] => 20210269754
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => CELL CULTURE SYSTEM
[patent_app_type] => utility
[patent_app_number] => 17/175856
[patent_app_country] => US
[patent_app_date] => 2021-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7778
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175856
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/175856 | CELL CULTURE SYSTEM | Feb 14, 2021 | Abandoned |
Array
(
[id] => 18212746
[patent_doc_number] => 20230059010
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => METHODS OF DIFFERENTIATING NEURAL CELLS AND RELATED COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/792632
[patent_app_country] => US
[patent_app_date] => 2021-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53713
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792632
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/792632 | METHODS OF DIFFERENTIATING NEURAL CELLS AND RELATED COMPOSITIONS AND METHODS OF USE | Jan 12, 2021 | Abandoned |
Array
(
[id] => 16933772
[patent_doc_number] => 20210199661
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => USE OF ZC3H12B GENE OR PROTEIN AND METHOD FOR ESTABLISHING ANIMAL MODEL OF LIVER DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/135890
[patent_app_country] => US
[patent_app_date] => 2020-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6037
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17135890
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/135890 | Use of ZC3H12B gene or protein and method for establishing animal model of liver disease | Dec 27, 2020 | Issued |
Array
(
[id] => 18126269
[patent_doc_number] => 20230011889
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-12
[patent_title] => GENETICALLY ENGINEERED DOUBLE NEGATIVE T CELLS AS AN ADOPTIVE CELLULAR THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/782071
[patent_app_country] => US
[patent_app_date] => 2020-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13012
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -60
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782071
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/782071 | GENETICALLY ENGINEERED DOUBLE NEGATIVE T CELLS AS AN ADOPTIVE CELLULAR THERAPY | Dec 6, 2020 | Pending |
Array
(
[id] => 17168809
[patent_doc_number] => 20210322479
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => METHODS FOR PREPARING PLATELET PRODUCTS
[patent_app_type] => utility
[patent_app_number] => 17/102269
[patent_app_country] => US
[patent_app_date] => 2020-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28874
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17102269
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/102269 | METHODS FOR PREPARING PLATELET PRODUCTS | Nov 22, 2020 | Abandoned |
Array
(
[id] => 16824290
[patent_doc_number] => 20210139583
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => PRODUCTION OF ENGINEERED T-CELLS BY SLEEPING BEAUTY TRANSPOSON COUPLED WITH METHOTREXATE SELECTION
[patent_app_type] => utility
[patent_app_number] => 17/096138
[patent_app_country] => US
[patent_app_date] => 2020-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37742
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17096138
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/096138 | Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection | Nov 11, 2020 | Issued |
Array
(
[id] => 18077730
[patent_doc_number] => 20220403342
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => METHOD FOR CULTURING GYNAECOLOGICAL TUMOUR PRIMARY CELLS AND MATCHING CULTURE MEDIUM
[patent_app_type] => utility
[patent_app_number] => 17/772203
[patent_app_country] => US
[patent_app_date] => 2020-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11050
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772203
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/772203 | METHOD FOR CULTURING GYNAECOLOGICAL TUMOUR PRIMARY CELLS AND MATCHING CULTURE MEDIUM | Nov 3, 2020 | Pending |
Array
(
[id] => 19003862
[patent_doc_number] => 20240067933
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-29
[patent_title] => MESH CHOPPING OF NEURAL PROGENITOR CELL AGGREGATES
[patent_app_type] => utility
[patent_app_number] => 17/766706
[patent_app_country] => US
[patent_app_date] => 2020-10-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9944
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766706
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/766706 | MESH CHOPPING OF NEURAL PROGENITOR CELL AGGREGATES | Oct 21, 2020 | Pending |
Array
(
[id] => 17020784
[patent_doc_number] => 20210244655
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/031207
[patent_app_country] => US
[patent_app_date] => 2020-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14381
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17031207
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/031207 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS | Sep 23, 2020 | Pending |
Array
(
[id] => 20757015
[patent_doc_number] => 12649774
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-06-09
[patent_title] => CAR-T cell compositions, methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/762186
[patent_app_country] => US
[patent_app_date] => 2020-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 53
[patent_figures_cnt] => 56
[patent_no_of_words] => 8374
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762186
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/762186 | CAR-T cell compositions, methods of use thereof | Sep 20, 2020 | Issued |
Array
(
[id] => 16656044
[patent_doc_number] => 20210052680
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => Stable Frozen Virus Formulation
[patent_app_type] => utility
[patent_app_number] => 17/012771
[patent_app_country] => US
[patent_app_date] => 2020-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11833
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17012771
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/012771 | Stable Frozen Virus Formulation | Sep 3, 2020 | Pending |
Array
(
[id] => 17807732
[patent_doc_number] => 20220259567
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => CULTURE METHOD AND CULTURE VESSEL
[patent_app_type] => utility
[patent_app_number] => 17/597744
[patent_app_country] => US
[patent_app_date] => 2020-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12190
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17597744
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/597744 | CULTURE METHOD AND CULTURE VESSEL | Jul 20, 2020 | Abandoned |
Array
(
[id] => 18673034
[patent_doc_number] => 20230310506
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => METHOD FOR ACTIVATING EXPRESSION OF GAMMA-GLOBIN GENE, AND COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 18/010448
[patent_app_country] => US
[patent_app_date] => 2020-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6867
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18010448
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/010448 | METHOD FOR ACTIVATING EXPRESSION OF GAMMA-GLOBIN GENE, AND COMPOSITION | Jul 13, 2020 | Pending |
Array
(
[id] => 20256133
[patent_doc_number] => 12428476
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-30
[patent_title] => System and methods relating to chimeric autoantibody receptors
[patent_app_type] => utility
[patent_app_number] => 16/927924
[patent_app_country] => US
[patent_app_date] => 2020-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 18
[patent_no_of_words] => 8939
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16927924
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/927924 | System and methods relating to chimeric autoantibody receptors | Jul 12, 2020 | Issued |
Array
(
[id] => 19410626
[patent_doc_number] => 12076419
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-03
[patent_title] => Lipin-1 as a novel therapy target of muscular dystrophy
[patent_app_type] => utility
[patent_app_number] => 16/907748
[patent_app_country] => US
[patent_app_date] => 2020-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 19
[patent_no_of_words] => 7939
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16907748
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/907748 | Lipin-1 as a novel therapy target of muscular dystrophy | Jun 21, 2020 | Issued |
Array
(
[id] => 17764430
[patent_doc_number] => 20220238042
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => ENGINEERED BONE MARROW MODEL
[patent_app_type] => utility
[patent_app_number] => 17/610401
[patent_app_country] => US
[patent_app_date] => 2020-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55957
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -111
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610401
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/610401 | ENGINEERED BONE MARROW MODEL | May 7, 2020 | Abandoned |
Array
(
[id] => 16328765
[patent_doc_number] => 20200299731
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => TARGETING PEPTIDE TO DELIVER A COMPOUND TO OOCYTES
[patent_app_type] => utility
[patent_app_number] => 15/929408
[patent_app_country] => US
[patent_app_date] => 2020-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28042
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15929408
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/929408 | Targeting peptide to deliver a compound to oocytes | Apr 29, 2020 | Issued |
Array
(
[id] => 17625756
[patent_doc_number] => 20220160771
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/602652
[patent_app_country] => US
[patent_app_date] => 2020-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25600
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602652
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/602652 | FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USING THE SAME | Apr 9, 2020 | Pending |